Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments.
Journal
Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
09
2022
accepted:
26
10
2022
pubmed:
6
11
2022
medline:
15
12
2022
entrez:
5
11
2022
Statut:
ppublish
Résumé
In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.
Identifiants
pubmed: 36334843
pii: S0755-4982(22)00037-9
doi: 10.1016/j.lpm.2022.104144
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104144Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest BC, AJ, SE, EM, AB, GL, MCV, DH, CCR, CB; none.